SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky
A securities class action alleges ARS Pharmaceuticals' public statements about a July 1, 2026 CVS Caremark formulary effective date were not accompanied by adequate warnings that the decision could slip to January 2027, and that SPRY shareholders lost $2.52 per share when the coverage...
Covered in this story
What has happened since
- Ars Pharmaceuticals Inc is up 3.3% since this was published, 29 days ago.
- CVS Health is up 10.0% since this was published, 29 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SPRY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ars Pharmaceuticals Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.